3) Sawaya BP, Koszewski NJ, Qi Q, et al. : Secondary hyperparathyroidism and vitamin D receptor binding to vitamin D response elements in rats with incipient renal fallure. J Am Soc Nephrol 8 : 271-278, 1997.
5) Brown EM : Extracelular calcium sensing and calcium signaUng. Physiol Rev 32 : 240-297, 2001.
9) Almaden Y, Canalejo A, Ballesteros E, et al. : Regulation of arachidonic acid production by intraceUular calcium in parathyroid cells : Effect of extraceUular phosphate. J Am Soc Nephrol 13 : 693-698, 2002.
15) Collins AJ, Peter WLS, Dalleska FW, et al. : Hospitahzation risks between Renagel phosphate binder treated and non-Renagel treated padents. Clm Nephrol 54 : 334-341, 2000.
17) Kinugasa E, Kishikawa S, The PB-94 Study Group : Effect of PB94 (sevelamer hydrochloride), aphosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients-A ramdomized, open label, dose titration study of PB-94 versus Caltan tablet 500 (calcium carbonate). J Am Soc Nephrol 12 (Suppl.) : A3943, 2001.
18) Joy MS, Finn WF, Lanthanum Study Group : Result of a randomized, phase, dose titration, paralel group study of lanthanum carbonate for reduction and maintenance of serum phosphate in chronic hemodialysis. J Am Soc Nephrol 12 (Suppl.) : A1996, 2001.
19) Joy MS, Finn WF, Lanthanum Study Group : Safety profile of lanthanum carbonate in hemodialysis padents ; Results from a phase III U. S. study. J Am Soc Nephrol 12 (Suppl.) : A1997, 2001.
20) Levine BS, Song M : Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 7 : 488-496, 1996.
21) Martin KJ, Gonzalez EA, Gellens M, et al. : 19-Nor-1α-25-dihydroxyvitamin D2 (Paricarcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9 : 1427-1432, 1998.
22) Tan AU, Levine BS, Mazess RB, et al. : Effective suppression of parathyroid hormone by 1α-hydroxyvitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney hlt 51 : 317-323, 1997.
23) Cozzolino M, Lu Y, Finch JL, et al. : p21 and TGF-α mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 60 : 2109-2117, 2001.
26) Goodman WG, Hladik GA, Tumer SA, et al. : The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13 : 1017-1024, 2002.
28) Giangrande A, Castigloni A, Solbiati L, et al. : Ultrasound-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrol Dial Transplant 7 : 412-421, 1992.
29) Sherrard DJ, Ott SM, Maloney N, et al. : Uremic osteodystrophy ; classification cause and treatment. In : Clinical Disorders of Bone and Mineral Metabolism (Frame B, Potts JT Jr, eds), Excepta Medica Amsterdam, 1983, pp254-259.
31) Gupta A, Kallenbach LR, Zasuwa G, et al. : Race is a major factor of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol 11 : 330-334, 2000.
35) Kazama J, Fukagawa M, Shigematsu T, et al. : Increased circulating osteoprotegerin modifies bone metabolism in uremic patients J Am Soc Nephrol 11 : 565A, 2000.